ZA982093B - Dolastatin-15 derivatives in combination with taxanes. - Google Patents

Dolastatin-15 derivatives in combination with taxanes.

Info

Publication number
ZA982093B
ZA982093B ZA9802093A ZA982093A ZA982093B ZA 982093 B ZA982093 B ZA 982093B ZA 9802093 A ZA9802093 A ZA 9802093A ZA 982093 A ZA982093 A ZA 982093A ZA 982093 B ZA982093 B ZA 982093B
Authority
ZA
South Africa
Prior art keywords
combination
dolastatin
taxanes
derivatives
compounds
Prior art date
Application number
ZA9802093A
Other languages
English (en)
Inventor
Teresa Barlozzari
Andreas Haupt
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA982093B publication Critical patent/ZA982093B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9802093A 1997-03-13 1998-03-12 Dolastatin-15 derivatives in combination with taxanes. ZA982093B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/819,101 US6103698A (en) 1997-03-13 1997-03-13 Dolastatin-15 derivatives in combination with taxanes

Publications (1)

Publication Number Publication Date
ZA982093B true ZA982093B (en) 1999-09-12

Family

ID=25227196

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9802093A ZA982093B (en) 1997-03-13 1998-03-12 Dolastatin-15 derivatives in combination with taxanes.

Country Status (29)

Country Link
US (2) US6103698A (de)
EP (1) EP0981358B1 (de)
JP (1) JP2001514659A (de)
KR (1) KR100555604B1 (de)
CN (1) CN1157223C (de)
AT (1) ATE241376T1 (de)
AU (1) AU728027B2 (de)
BG (1) BG64338B1 (de)
BR (1) BR9808249A (de)
CA (1) CA2282720C (de)
CO (1) CO4940498A1 (de)
CZ (1) CZ293905B6 (de)
DE (1) DE69815100T2 (de)
DK (1) DK0981358T3 (de)
ES (1) ES2200317T3 (de)
HR (1) HRP980125A2 (de)
HU (1) HU228860B1 (de)
ID (1) ID23900A (de)
IL (2) IL131597A0 (de)
NO (1) NO323894B1 (de)
NZ (1) NZ337416A (de)
PL (1) PL197834B1 (de)
PT (1) PT981358E (de)
RU (1) RU2218174C2 (de)
SK (1) SK285133B6 (de)
TR (1) TR199902244T2 (de)
TW (1) TWI277426B (de)
WO (1) WO1998040092A1 (de)
ZA (1) ZA982093B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1333847A1 (de) * 2000-11-08 2003-08-13 Lorus Therapeutics Inc. Kombinationpräparate enthltend biologische verhaltensändernde stoffe und krebsmittel und ihre verwendung
US20050192443A1 (en) * 2000-11-08 2005-09-01 Lorus Therapeutics Inc. Biological response modifier for the treatment of cancer
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
EP4144747A4 (de) * 2020-06-03 2024-05-29 Chugai Seiyaku Kabushiki Kaisha Effizientes peptidkondensationsverfahren für schwierige sequenzen
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5676978A (en) 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
DE69232552T2 (de) 1991-08-09 2002-10-31 Teikoku Hormone Mfg. Co., Ltd. Tetrapeptide Derivat
US5227400A (en) * 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5250683A (en) * 1991-09-23 1993-10-05 Florida State University Certain substituted taxanes and pharmaceutical compositions containing them
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
FR2688518B1 (fr) * 1992-03-13 1994-05-06 Rhone Poulenc Rorer Sa Procede de preparation de derives du taxane.
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
US5248796A (en) * 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DE69329425T2 (de) * 1992-12-16 2001-01-18 Basf Ag Dolastatin analog
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
CA2129282A1 (en) 1993-09-29 1995-03-30 George Weber Method for the treatment of neoplastic disease utilizing taxol and tiazofurin
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5494930A (en) * 1994-06-02 1996-02-27 Shimizu; Yuzuru Caribenolide I
US5525613A (en) * 1994-06-16 1996-06-11 Entropin, Inc. Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
ATE306927T1 (de) 1994-12-15 2005-11-15 Baker Norton Pharma Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung

Also Published As

Publication number Publication date
CA2282720C (en) 2009-12-29
HUP0001381A2 (hu) 2000-10-28
RU2218174C2 (ru) 2003-12-10
NO323894B1 (no) 2007-07-16
AU728027B2 (en) 2001-01-04
KR20000076211A (ko) 2000-12-26
TWI277426B (en) 2007-04-01
IL131597A (en) 2006-06-11
SK125199A3 (en) 2000-08-14
KR100555604B1 (ko) 2006-03-03
JP2001514659A (ja) 2001-09-11
ATE241376T1 (de) 2003-06-15
DE69815100D1 (de) 2003-07-03
BG103728A (en) 2000-04-28
BR9808249A (pt) 2000-05-16
US6103698A (en) 2000-08-15
NO994408L (no) 1999-11-10
ES2200317T3 (es) 2004-03-01
SK285133B6 (sk) 2006-07-07
PT981358E (pt) 2003-09-30
EP0981358B1 (de) 2003-05-28
AU6694598A (en) 1998-09-29
HRP980125A2 (en) 1999-02-28
CO4940498A1 (es) 2000-07-24
ID23900A (id) 2000-05-25
DE69815100T2 (de) 2004-02-05
DK0981358T3 (da) 2003-09-22
CZ293905B6 (cs) 2004-08-18
NO994408D0 (no) 1999-09-10
HK1026851A1 (en) 2000-12-29
PL335579A1 (en) 2000-05-08
CZ321199A3 (cs) 2000-02-16
IL131597A0 (en) 2001-01-28
HU228860B1 (en) 2013-06-28
TR199902244T2 (xx) 1999-12-21
US6632795B1 (en) 2003-10-14
HUP0001381A3 (en) 2001-12-28
NZ337416A (en) 2001-05-25
WO1998040092A1 (en) 1998-09-17
PL197834B1 (pl) 2008-04-30
CA2282720A1 (en) 1998-09-17
BG64338B1 (bg) 2004-10-29
CN1252728A (zh) 2000-05-10
CN1157223C (zh) 2004-07-14
EP0981358A1 (de) 2000-03-01

Similar Documents

Publication Publication Date Title
ES2151277T3 (es) Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
FI952248A7 (fi) Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia
NZ514409A (en) C7 ester substituted taxanes as antitumor agents
ATE342054T1 (de) Verfahren und zusammansetzung zur behandlung von krebs
NZ245795A (en) The use of paclitaxel formulations with reduced haematologic toxicity to treat tumours
HUT67742A (en) Phosphono-oxymethyl-ethers of taxane derivatives
HU9602942D0 (en) Taxane class derivative based pharmaceutical compositions
WO2002058694A3 (en) Method of treating hematologic tumors and cancers using beta lapachone
IL109613A (en) Inclusion complexes of taxol or taxotere or taxus extract formed with cyclodextrins, their preparation and use
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
ZA982093B (en) Dolastatin-15 derivatives in combination with taxanes.
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
DE69430797D1 (de) C9 taxanderivate und diese enthaltende pharmazeutische zusammensetzungen
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
IL145640A0 (en) C10 carbamoyloxy substituted taxanes as antitumor agents
AU4558201A (en) Taxane anticancer agents
EP0793499A4 (de) Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung
SI1287854T1 (sl) Kombinacija DMXAA in paklitaksela ali docetakselaproti raku
HUP0103246A2 (hu) C10 karbonát szubsztituált taxánok
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
HUP0103247A2 (hu) C7 észter szubsztituált taxánok